AU2020225455A1 - Solid forms of condensed pyrazines as Syk inhibitors - Google Patents

Solid forms of condensed pyrazines as Syk inhibitors Download PDF

Info

Publication number
AU2020225455A1
AU2020225455A1 AU2020225455A AU2020225455A AU2020225455A1 AU 2020225455 A1 AU2020225455 A1 AU 2020225455A1 AU 2020225455 A AU2020225455 A AU 2020225455A AU 2020225455 A AU2020225455 A AU 2020225455A AU 2020225455 A1 AU2020225455 A1 AU 2020225455A1
Authority
AU
Australia
Prior art keywords
compound
sesqui
ray powder
powder diffractogram
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020225455A
Other languages
English (en)
Inventor
Patricia Andres
Peter C. FUNG
Pierre Giguere
Chiajen Lai
Craig Stewart
Jing TENG
Duong D. TRAN
Iva TRANTCHEVA
Brian YARMUCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kronos Bio Inc
Original Assignee
Kronos Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc
Publication of AU2020225455A1 publication Critical patent/AU2020225455A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020225455A 2019-02-22 2020-02-20 Solid forms of condensed pyrazines as Syk inhibitors Abandoned AU2020225455A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809337P 2019-02-22 2019-02-22
US62/809,337 2019-02-22
PCT/US2020/019071 WO2020172431A1 (en) 2019-02-22 2020-02-20 Solid forms of condensed pyrazines as syk inhibitors

Publications (1)

Publication Number Publication Date
AU2020225455A1 true AU2020225455A1 (en) 2021-09-09

Family

ID=69845599

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020225455A Abandoned AU2020225455A1 (en) 2019-02-22 2020-02-20 Solid forms of condensed pyrazines as Syk inhibitors

Country Status (11)

Country Link
US (3) US11339168B2 (enExample)
EP (1) EP3927708A1 (enExample)
JP (1) JP2022521413A (enExample)
KR (1) KR20210131372A (enExample)
CN (1) CN113950479A (enExample)
AU (1) AU2020225455A1 (enExample)
CA (1) CA3130848A1 (enExample)
MX (1) MX2021010131A (enExample)
TW (1) TW202045510A (enExample)
WO (1) WO2020172431A1 (enExample)
ZA (1) ZA202106014B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US20240285621A1 (en) 2020-09-23 2024-08-29 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
CN112939983A (zh) * 2021-02-01 2021-06-11 暨明医药科技（苏州）有限公司 一种SYK激酶抑制剂Lanraplenib的合成方法
EP4646412A1 (en) * 2022-12-09 2025-11-12 Kronos Bio, Inc. Crystalline forms of lanraplenib and methods of making and using the same

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6249495B1 (en) 1997-02-27 2001-06-19 Matsushita Electric Industrial Co., Ltd. Stepping motor control method and disk drive apparatus
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2001275076A1 (en) 2000-06-19 2002-01-02 Armin S. Tay Axial position changing transmission mechanism
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2001297846A1 (en) 2000-11-20 2002-12-23 Cryoco, Inc. A method and apparatus for the preparation and usage of a cryogenic propellant or explosive system
DK174233B1 (da) 2000-12-27 2002-10-07 Dss Danish Separation Systems Sanitært spiralfilteranlæg
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7003125B2 (en) 2001-09-12 2006-02-21 Seung-Hwan Yi Micromachined piezoelectric microspeaker and fabricating method thereof
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
KR20050008691A (ko) 2002-04-19 2005-01-21 셀룰러 지노믹스 아이엔씨 이미다조[1,2-ａ]피라진-8-일 아민, 그의 제조방법 및사용방법
KR101060971B1 (ko) 2002-05-14 2011-09-01 제노바 리미티드 안트라닐산 유도체 수화물의 제조 방법
KR20040012451A (ko) 2002-05-14 2004-02-11 어플라이드 머티어리얼스, 인코포레이티드 포토리소그래픽 레티클을 에칭하는 방법
JP2004053714A (ja) 2002-07-17 2004-02-19 Fuji Xerox Co Ltd 画像定着装置及び画像定着方法
US6761361B2 (en) 2002-08-09 2004-07-13 Credo Technology Corporation Drill and drive apparatus with improved tool holder
US20040026867A1 (en) 2002-08-09 2004-02-12 Adams David J. Bearing seal
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
MY133311A (en) 2002-09-19 2007-11-30 Schering Corp Novel imidazopyridines as cyclin dependent kinase inhibitors
NZ538686A (en) 2002-09-23 2008-01-31 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
NZ538685A (en) 2002-09-23 2008-02-29 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
JP4056346B2 (ja) 2002-09-30 2008-03-05 三洋電機株式会社 非水電解質二次電池
PT1581236E (pt) 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7456393B2 (en) 2003-04-10 2008-11-25 Ge Homeland Protection, Inc. Device for testing surfaces of articles for traces of explosives and/or drugs
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US7236749B2 (en) 2003-10-15 2007-06-26 Honeywell International Inc. Stuck microphone deselection system and method
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
EA011446B1 (ru) 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
JP2006099930A (ja) 2004-09-01 2006-04-13 Tdk Corp 情報記録媒体、記録再生装置およびスタンパー
US8145601B2 (en) 2004-09-09 2012-03-27 Microsoft Corporation Method, system, and apparatus for providing resilient data transfer in a data protection system
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2005304473A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
CN101124227A (zh) 2004-11-10 2008-02-13 Cgi制药有限公司 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
JP4883959B2 (ja) 2005-08-17 2012-02-22 Ｎｔｎ株式会社 回転検出装置および回転検出装置付き軸受
US20070117804A1 (en) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
JP4837378B2 (ja) 2006-01-04 2011-12-14 株式会社日立製作所 データの改竄を防止する記憶装置
US7446352B2 (en) 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
DE102006032495A1 (de) 2006-07-13 2008-02-07 Nokia Siemens Networks Gmbh & Co.Kg Verfahren und Vorrichtung zur Vermeidung von Interferenzen in einem zellulären Funkkommunikationssystem
US20080025821A1 (en) 2006-07-25 2008-01-31 Applied Materials, Inc. Octagon transfer chamber
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
JP5563472B2 (ja) 2007-11-28 2014-07-30 アイ アール エックス セーラピューティクス， インコーポレイテッド 免疫学的効果を増大させる方法
JP5643105B2 (ja) 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
AR075257A1 (es) 2008-02-01 2011-03-23 Hexima Ltd Sistema de proteccion de plantas contra la infeccion por agentes patogenos
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
WO2009102252A1 (en) 2008-02-15 2009-08-20 Telefonaktiebolaget L M Ericsson (Publ) A method of accessing a communications channel
WO2009109844A1 (en) 2008-03-07 2009-09-11 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
CA2723237A1 (en) 2008-05-06 2009-11-12 Peter A. Blomgren Substituted amides, method of making, and use as btk inhibitors
PH12012502374A1 (en) 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es) 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
WO2010006947A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
PL2716157T3 (pl) 2008-12-08 2017-06-30 Gilead Connecticut, Inc. Imidazopirazynowe inhibitory Syk
PE20120121A1 (es) 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20110099133A1 (en) 2009-10-28 2011-04-28 Industrial Technology Research Institute Systems and methods for capturing and managing collective social intelligence information
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
NZ601267A (en) * 2009-12-23 2014-03-28 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
EP2703400A4 (en) 2011-04-27 2014-10-08 Daiichi Sankyo Co Ltd PHENYLPYRROLDERIVAT CRYSTAL
WO2013188856A1 (en) 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
AU2013302617A1 (en) 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
PE20160605A1 (es) 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
KR20160090903A (ko) 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
CA2983611A1 (en) 2015-04-21 2016-10-27 Gilead Sciences, Inc. Treatment of chronic graft versus host disease with syk inhibitors
AU2017325844A1 (en) 2016-09-14 2019-03-07 Gilead Sciences, Inc. SYK inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑

Also Published As

Publication number Publication date
MX2021010131A (es) 2021-11-18
CN113950479A (zh) 2022-01-18
US20200291035A1 (en) 2020-09-17
CA3130848A1 (en) 2020-08-27
US12152037B2 (en) 2024-11-26
TW202045510A (zh) 2020-12-16
US20250313566A1 (en) 2025-10-09
WO2020172431A1 (en) 2020-08-27
KR20210131372A (ko) 2021-11-02
JP2022521413A (ja) 2022-04-07
ZA202106014B (en) 2024-01-31
US11339168B2 (en) 2022-05-24
EP3927708A1 (en) 2021-12-29
US20230098309A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US12263163B2 (en) Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor
US12152037B2 (en) Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor
EP3169329A1 (en) Syk inhibitors
MX2013005603A (es) Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
HK1256999B (en) Syk inhibitors
OA20934A (en) Syk inhibitors
BR122020009305B1 (pt) Forma cristalina de 6-(6-aminopirazin-2-il)-n-(4-(4-(oxetan-3-il)piperazin-1- il)fenil)imidazo[1,2-a]pirazin-8-amina, composição farmacêutica, e, uso de uma forma cristalina
HK1230609A1 (en) Syk inhibitors
HK1230609B (en) Syk inhibitors
OA18627A (en) Syk inhibitors.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application